Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug664 | Blood sampling (venesection) Wiki | 0.58 |
| drug4144 | Standardised questionnaires Wiki | 0.58 |
| drug666 | Blood test for IgG antibodies against SARS-CoV-2 Wiki | 0.58 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D001049 | Apnea NIH | 1.00 |
| D012891 | Sleep Apnea, NIH | 0.71 |
| D020181 | Sleep Apnea, Obstructive NIH | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002870 | Obstructive sleep apnea HPO | 0.71 |
| HP:0010535 | Sleep apnea HPO | 0.71 |
| HP:0006536 | Pulmonary obstruction HPO | 0.14 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0006510 | Chronic pulmonary obstruction HPO | 0.13 |
| HP:0002088 | Abnormal lung morphology HPO | 0.10 |
| HP:0002090 | Pneumonia HPO | 0.03 |
Navigate: Correlations HPO
There are 3 clinical trials
Covid-19 infection is an on-going pandemic with worse diagnosis in adults with comorbid conditions such as hypertension and cardiopulmonary diseases. Obstructive sleep apnea (OSA) is common in those comorbidities and may contribute to worse prognosis for the Covid-19 cases.
Description: Defined as a decline of 2 categories from admission on a 7-category ordinal scale
Measure: The rate of clinical improvement Time: 7 daysDescription: Defined as a decline of 2 categories from admission on a 7-category ordinal scale
Measure: The rate of clinical improvement Time: 14 daysDescription: Defined as a decline of 2 categories from admission on a 7-category ordinal scale
Measure: The rate of clinical improvement Time: 21 daysDescription: Defined as a decline of 2 categories from admission on a 7-category ordinal scale
Measure: The rate of clinical improvement Time: 28 daysDescription: Time to hospital discharge, ICU discharge, weaning from intubation, weaning from supplemental oxygen, incident pneumonia, ARDS, in-hospital mortality
Measure: Clinical status - improvement Time: 7, 14, 21, 28 daysDescription: Defined as an increase in category on a 7-category ordinal scale from admission
Measure: Clinical status - worsening Time: 7, 14, 21, 28 daysDescription: Re-analysis of the correlation of obstructive sleep apnea (objectively verified) severity in terms of apnea-hypopnea index and oxygenation levels with the primary and secondary outcomes as described above (the rate of clinical improvement defined as a decline of 2 categories from admission on a 7-category ordinal scale; time to hospital discharge, ICU discharge, weaning from intubation, weaning from supplemental oxygen, incident pneumonia, ARDS, in-hospital mortality as well as with the lung function, CO-diffusion capacity, cardiac function, CT thorax pathologies, biomarkers (cytokines, polymorphisms) and IgG-antibodies after 4 months.
Measure: Long-term outcomes Time: 4-6 months after the initial hospital admissionThis study will evaluate the influence of sleep apnea on clinical and radiological features of MS. Sleep apnea is associated with hypoxemia during sleep, which we believe is detrimental to MS. We will examine clinical data (MRI, lab results, medical history, labs, and sleep studies) of Dr. Sloane's MS patients. This will allow us to study correlations between MRI, clinical data, lab studies and sleep studies. We are specifically interested in the type of sleep apnea associated with MS, and whether MRI or clinical metrics of MS severity correlate with presence or absence of sleep apnea.
Description: Home Sleep Study Data
Measure: Home Sleep Study Data Time: 1 yearDescription: sleep quality, quality of life, depression and anxiety scales
Measure: Questionnaire data Time: 1 yearThe primary purpose of the study is to determine whether lemborexant increases the apnea hypopnea index (AHI) on Day 8 of treatment in adult and elderly participants (adults greater than or equal to [>=] 45 to less than [<] 65 years; elderly >=65 to 90 years) with moderate to severe obstructive sleep apnea (OSA) compared with placebo, and using pulse oximetry determine whether lemborexant decreases the peripheral oxygen saturation (SpO2) during total sleep time (TST) on Day 8 of treatment in adult and elderly participants (adults >=45 to <65 years; elderly >=65 to 90 years) with moderate to severe chronic obstructive pulmonary disease (COPD) compared with placebo.
Description: AHI is defined as the average number of apneas and hypopneas per hour of sleep. AHI will be assessed using polysomnography (PSG). The International Classification of Sleep Disorders (ICSD) (American Academy of Sleep Medicine, 2014) defines the severity of OSA according to the AHI: an AHI >5 to <15 is classed as mild, AHI >=15 to <30 as moderate, and AHI >=30 as severe.
Measure: OSA Cohort: AHI on Day 8 of Treatment Time: Day 8Description: SpO2 is an estimate of the amount of oxygen in the blood. It is the percentage of hemoglobin containing oxygen compared to the total amount of hemoglobin in the blood (that is, oxygenated hemoglobin versus oxygenated and non-oxygenated hemoglobin). SpO2 is monitored by noninvasive method known as transmissive pulse oximetry. TST is defined as the total time asleep in minutes using PSG.
Measure: COPD Cohort: Mean SpO2 During TST on Day 8 of Treatment Time: Day 8Description: AHI is defined as the average number of apneas and hypopneas per hour of sleep. AHI will be assessed using PSG. The ICSD (American Academy of Sleep Medicine, 2014) defines the severity of OSA according to the AHI: an AHI >5 to <15 is classed as mild, AHI >=15 to <30 as moderate, and AHI >=30 as severe.
Measure: AHI on Day 1 and Day 8 of Treatment Time: OSA Cohort: Day 1; COPD Cohort: Day 1 and Day 8Description: SpO2 is an estimate of the amount of oxygen in the blood. It is the percentage of hemoglobin containing oxygen compared to the total amount of hemoglobin in the blood (that is, oxygenated hemoglobin versus oxygenated and non-oxygenated hemoglobin). SpO2 is monitored by noninvasive method known as transmissive pulse oximetry. TST is defined as the total time asleep in minutes using PSG.
Measure: Mean SpO2 During TST on Day 1 and Day 8 of Treatment Time: OSA Cohort: Day 1 and Day 8; COPD Cohort: Day 1Description: SpO2 is an estimate of the amount of oxygen in the blood. It is the percentage of hemoglobin containing oxygen compared to the total amount of hemoglobin in the blood (that is, oxygenated hemoglobin versus oxygenated and non-oxygenated hemoglobin). SpO2 is monitored by noninvasive method known as transmissive pulse oximetry. TST is defined as the total time asleep in minutes using PSG.
Measure: Percentage of TST During Which the SpO2 is <90 percent (%), <85% and <80% on Day 1 and Day 8 of Treatment Time: Day 1 and Day 8Description: ODI is defined as (oxygen desaturations >=3%*60)/TST (that is, the average number of oxygen desaturations >=3% per hour of sleep), as defined by the American Academy of Sleep Medicine. ODI will be assessed using PSG.
Measure: Mean Oxygen Desaturation Index (ODI) on Days 1 and 8 of Treatment Time: Day 1 and Day 8Description: Desaturation is defined as decrease in the mean SpO2 of >=3% (over the last 120 seconds) that lasts for at least 10 seconds. Desaturation will be assessed using PSG.
Measure: Absolute Number of Desaturations (>=3% Reduction From Baseline SpO2) on Days 1 and 8 of Treatment Time: Day 1 and Day 8Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports